FibroBiologics Secures Canadian Patent for Cachexia Treatment
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 05 2026
0mins
Should l Buy FBLG?
Source: Newsfilter
- Patent Issuance: FibroBiologics has secured Canadian Patent No. 3118732, focusing on the use of fibroblast cells to treat cachexia, further solidifying its intellectual property portfolio of over 270 patents and demonstrating the company's commitment to innovation in chronic disease therapies.
- Market Potential: The cachexia market related to cancer is projected to reach $3.2 billion by 2032, and this new patent provides FibroBiologics with a unique market opportunity that could significantly enhance its competitiveness in the biotechnology sector.
- Innovative Treatment Methods: The patent covers methods using immune-modulating fibroblasts cultured under specific conditions to suppress inflammation and address the root causes of cachexia, potentially offering new treatment options that improve patient quality of life.
- Strategic Importance: CEO Pete O'Heeron stated that the issuance of this patent not only expands global IP protection but also brings the company closer to delivering transformative therapies that could change the standard of care for millions of patients worldwide.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy FBLG?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on FBLG
Wall Street analysts forecast FBLG stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 2.280
Low
1.50
Averages
3.25
High
5.00
Current: 2.280
Low
1.50
Averages
3.25
High
5.00
About FBLG
FibroBiologics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with significant unmet medical needs, including wound healing, multiple sclerosis, degenerative disc disease, psoriasis and certain cancers, and potential human longevity applications including thymic involution reversal. Its product candidates include CybroCell, CYMS101 and CYWC628. CybroCell is an allogeneic fibroblast cell-based therapy for degenerative disc disease. This technology is being designed as an alternative method for repairing the cartilage of the intervertebral disc (or any other articular cartilage). It is developing CYMS101 as an allogeneic fibroblast cell-based therapy to treat multiple sclerosis (MS) and has completed the Phase I study. It is developing CYWC628 as an allogeneic fibroblast cell-based therapy for wound healing. Its CYPS317 is used for the treatment of Psoriasis.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
FibroBiologics Files for $5M Public Offering Amid Reverse Split
- Public Offering Plan: FibroBiologics has filed an amended registration statement for a public offering of approximately 1.14 million units, expected to raise about $5 million in gross proceeds to support the company's operations and development.
- Reverse Split Strategy: This offering is strategically timed with a 1-for-20 reverse stock split effective March 30, 2026, aimed at elevating the company's share price to comply with Nasdaq's $1.00 minimum bid price requirement, thereby enhancing market confidence.
- Unit Composition Details: Each unit consists of one share of common stock (or one pre-funded warrant) and one common warrant priced at $4.40 per unit, with warrants expiring five years after issuance or stockholder approval, increasing potential returns for investors.
- Planned Use of Proceeds: The company intends to utilize the net proceeds (approximately $4.3 million) for working capital and general corporate purposes, including the continued development of its fibroblast-based therapeutic pipeline, demonstrating its commitment to future growth.
See More
FibroBiologics Approves 1-for-20 Reverse Stock Split
- Reverse Split Decision: FibroBiologics' board approved a 1-for-20 reverse stock split to meet Nasdaq Capital Market's minimum bid price requirements, thereby mitigating delisting risks and enhancing market confidence.
- Effective Date: The reverse split will take effect on March 30, with trading on a split-adjusted basis starting the same day, reducing outstanding shares from approximately 70.3 million to about 3.5 million, significantly increasing the per-share value.
- Shareholder Authorization: This reverse split has been previously authorized by shareholders, indicating the company's commitment to maintaining its listing status while potentially attracting more investor interest in its stock.
- Market Reaction Expectations: By implementing the reverse split, FibroBiologics aims to restore compliance and boost investor interest; although it may face market volatility in the short term, it is expected to improve the company's image and shareholder value in the long run.
See More
FibroBiologics Approves 1-for-20 Reverse Stock Split
- Reverse Stock Split Plan: FibroBiologics' Board of Directors has approved a 1-for-20 reverse stock split effective March 30, 2026, reducing the outstanding shares from 70,256,883 to approximately 3,512,845 shares, aimed at regaining compliance with Nasdaq's minimum bid price requirement and enhancing investor interest.
- Shareholder Meeting Approval: The reverse stock split plan was approved at a special shareholder meeting on February 20, 2026, with the Board determining that this timing is appropriate to improve the company's market performance and attract more investors.
- Share Adjustment Mechanism: Following the reverse split, all shareholders' ownership percentages will remain unchanged, except for fractional shares which will be rounded up to the nearest whole share, ensuring that shareholder rights are preserved.
- Trading Adjustment Arrangements: VStock Transfer, LLC will act as the exchange agent for the reverse stock split, with shareholders holding shares in book-entry form or through brokerage accounts having their positions automatically adjusted without requiring any action, ensuring a smooth trading process.
See More
FIBROBIOLOGICS INC - BOARD AUTHORIZES 1-FOR-20 REVERSE STOCK SPLIT
- Approval of Stock Split: FibroGen's Board has approved a 1-for-20 reverse stock split.
- Purpose of the Split: The reverse stock split aims to increase the per-share price of the company's stock.
See More
Avaí Bio Initiates Production of α-Klotho Cell Bank
- Production Milestone: Avaí Bio, in collaboration with Austrianova, has initiated the production of a Master Cell Bank for the α-Klotho protein, marking a significant transition of its anti-aging program from research to manufacturing, which is expected to enhance the market potential for anti-aging therapies.
- Market Outlook: The global cell and gene therapy market is projected to surge from $10.4 billion to over $45 billion, with Avaí Bio's dual-program strategy targeting major diseases like Alzheimer's and diabetes, leveraging this growth trend effectively.
- Technological Edge: Utilizing the Cell-in-a-Box® technology backed by over 50 peer-reviewed studies, Avaí Bio ensures the efficacy of its products in anti-aging and diabetes treatments, thereby enhancing its competitive position in the biotechnology sector.
- Health Implications: Research links α-Klotho to reduced risks of Alzheimer's, cardiovascular diseases, and certain cancers, and Avaí Bio's products aim to address the therapeutic gap created by the natural decline of α-Klotho levels after age 40, meeting the rising market demand.
See More
FibroBiologics Completes Onboarding for DFU Clinical Trial
- Clinical Trial Launch: FibroBiologics has completed the onboarding of clinical sites for the CYWC628 trial, marking a critical step in its research for treating refractory diabetic foot ulcers, potentially offering new treatment options for patients.
- Trial Design Details: This trial is a prospective, multicenter, open-label study where participants will receive up to 12 weeks of treatment, comparing standard care with low or high doses of CYWC628 to evaluate its safety and tolerability.
- Data Generation Plan: The trial will assess wound healing outcomes and safety parameters through regular clinical observations, testing, and imaging evaluations, with an interim analysis planned after participants complete six weeks of treatment to evaluate primary safety and efficacy endpoints.
- Partner Support: Southern Star Research will manage all aspects of the CYWC628 trial, leveraging its expertise in complex early-phase trials to ensure high-quality data generation that supports FibroBiologics' innovative therapy.
See More
FibroBiologics Files for $5M Public Offering Amid Reverse Split
- Public Offering Plan: FibroBiologics has filed an amended registration statement for a public offering of approximately 1.14 million units, expected to raise about $5 million in gross proceeds to support the company's operations and development.
- Reverse Split Strategy: This offering is strategically timed with a 1-for-20 reverse stock split effective March 30, 2026, aimed at elevating the company's share price to comply with Nasdaq's $1.00 minimum bid price requirement, thereby enhancing market confidence.
- Unit Composition Details: Each unit consists of one share of common stock (or one pre-funded warrant) and one common warrant priced at $4.40 per unit, with warrants expiring five years after issuance or stockholder approval, increasing potential returns for investors.
- Planned Use of Proceeds: The company intends to utilize the net proceeds (approximately $4.3 million) for working capital and general corporate purposes, including the continued development of its fibroblast-based therapeutic pipeline, demonstrating its commitment to future growth.
See More
FibroBiologics Approves 1-for-20 Reverse Stock Split
- Reverse Split Decision: FibroBiologics' board approved a 1-for-20 reverse stock split to meet Nasdaq Capital Market's minimum bid price requirements, thereby mitigating delisting risks and enhancing market confidence.
- Effective Date: The reverse split will take effect on March 30, with trading on a split-adjusted basis starting the same day, reducing outstanding shares from approximately 70.3 million to about 3.5 million, significantly increasing the per-share value.
- Shareholder Authorization: This reverse split has been previously authorized by shareholders, indicating the company's commitment to maintaining its listing status while potentially attracting more investor interest in its stock.
- Market Reaction Expectations: By implementing the reverse split, FibroBiologics aims to restore compliance and boost investor interest; although it may face market volatility in the short term, it is expected to improve the company's image and shareholder value in the long run.
See More
FibroBiologics Approves 1-for-20 Reverse Stock Split
- Reverse Stock Split Plan: FibroBiologics' Board of Directors has approved a 1-for-20 reverse stock split effective March 30, 2026, reducing the outstanding shares from 70,256,883 to approximately 3,512,845 shares, aimed at regaining compliance with Nasdaq's minimum bid price requirement and enhancing investor interest.
- Shareholder Meeting Approval: The reverse stock split plan was approved at a special shareholder meeting on February 20, 2026, with the Board determining that this timing is appropriate to improve the company's market performance and attract more investors.
- Share Adjustment Mechanism: Following the reverse split, all shareholders' ownership percentages will remain unchanged, except for fractional shares which will be rounded up to the nearest whole share, ensuring that shareholder rights are preserved.
- Trading Adjustment Arrangements: VStock Transfer, LLC will act as the exchange agent for the reverse stock split, with shareholders holding shares in book-entry form or through brokerage accounts having their positions automatically adjusted without requiring any action, ensuring a smooth trading process.
See More
FIBROBIOLOGICS INC - BOARD AUTHORIZES 1-FOR-20 REVERSE STOCK SPLIT
- Approval of Stock Split: FibroGen's Board has approved a 1-for-20 reverse stock split.
- Purpose of the Split: The reverse stock split aims to increase the per-share price of the company's stock.
See More
Avaí Bio Initiates Production of α-Klotho Cell Bank
- Production Milestone: Avaí Bio, in collaboration with Austrianova, has initiated the production of a Master Cell Bank for the α-Klotho protein, marking a significant transition of its anti-aging program from research to manufacturing, which is expected to enhance the market potential for anti-aging therapies.
- Market Outlook: The global cell and gene therapy market is projected to surge from $10.4 billion to over $45 billion, with Avaí Bio's dual-program strategy targeting major diseases like Alzheimer's and diabetes, leveraging this growth trend effectively.
- Technological Edge: Utilizing the Cell-in-a-Box® technology backed by over 50 peer-reviewed studies, Avaí Bio ensures the efficacy of its products in anti-aging and diabetes treatments, thereby enhancing its competitive position in the biotechnology sector.
- Health Implications: Research links α-Klotho to reduced risks of Alzheimer's, cardiovascular diseases, and certain cancers, and Avaí Bio's products aim to address the therapeutic gap created by the natural decline of α-Klotho levels after age 40, meeting the rising market demand.
See More
FibroBiologics Completes Onboarding for DFU Clinical Trial
- Clinical Trial Launch: FibroBiologics has completed the onboarding of clinical sites for the CYWC628 trial, marking a critical step in its research for treating refractory diabetic foot ulcers, potentially offering new treatment options for patients.
- Trial Design Details: This trial is a prospective, multicenter, open-label study where participants will receive up to 12 weeks of treatment, comparing standard care with low or high doses of CYWC628 to evaluate its safety and tolerability.
- Data Generation Plan: The trial will assess wound healing outcomes and safety parameters through regular clinical observations, testing, and imaging evaluations, with an interim analysis planned after participants complete six weeks of treatment to evaluate primary safety and efficacy endpoints.
- Partner Support: Southern Star Research will manage all aspects of the CYWC628 trial, leveraging its expertise in complex early-phase trials to ensure high-quality data generation that supports FibroBiologics' innovative therapy.
See More
